One of the largest and best-documented trials of children receiving early antiretroviral therapy — the CHER clinical trial in South Africa — finds ongoing white matter damage in HIV-positive children at the age of 7 years. The study aims to contribute to a better understanding of brain development in HIV-infected and exposed children, as well as the impact of long-term antiretroviral treatment.